Literature DB >> 18811724

Mutations of maturity-onset diabetes of the young (MODY) genes in Thais with early-onset type 2 diabetes mellitus.

Nattachet Plengvidhya1, Watip Boonyasrisawat, Nalinee Chongjaroen, Prapaporn Jungtrakoon, Sutin Sriussadaporn, Sathit Vannaseang, Napatawn Banchuin, Pa-thai Yenchitsomanus.   

Abstract

OBJECTIVE: Six known genes responsible for maturity-onset diabetes of the young (MODY) were analysed to evaluate the prevalence of their mutations in Thai patients with MODY and early-onset type 2 diabetes. PATIENTS AND METHODS: Fifty-one unrelated probands with early-onset type 2 diabetes, 21 of them fitted into classic MODY criteria, were analysed for nucleotide variations in promoters, exons, and exon-intron boundaries of six known MODY genes, including HNF-4alpha, GCK, HNF-1alpha, IPF-1, HNF-1beta, and NeuroD1/beta2, by the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) method followed by direct DNA sequencing. Missense mutations or mutations located in regulatory region, which were absent in 130 chromosomes of non-diabetic controls, were classified as potentially pathogenic mutations.
RESULTS: We found that mutations of the six known MODY genes account for a small proportion of classic MODY (19%) and early-onset type 2 diabetes (10%) in Thais. Five of these mutations are novel including GCK R327H, HNF-1alpha P475L, HNF-1alphaG554fsX556, NeuroD1-1972 G > A and NeuroD1 A322N. Mutations of IPF-1 and HNF-1beta were not identified in the studied probands.
CONCLUSIONS: Mutations of the six known MODY genes may not be a major cause of MODY and early-onset type 2 diabetes in Thais. Therefore, unidentified genes await discovery in a majority of Thai patients with MODY and early-onset type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18811724     DOI: 10.1111/j.1365-2265.2008.03397.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Mutations in KCNJ11 are associated with the development of autosomal dominant, early-onset type 2 diabetes.

Authors:  Limei Liu; Kazuaki Nagashima; Takao Yasuda; Yanjun Liu; Hai-Rong Hu; Guang He; Bo Feng; Mingming Zhao; Langen Zhuang; Taishan Zheng; Theodore C Friedman; Kunsan Xiang
Journal:  Diabetologia       Date:  2013-09-10       Impact factor: 10.122

2.  Importance of glucokinase -258G/A polymorphism in Asian Indians with post-transplant and type 2 diabetes mellitus.

Authors:  Imran Ali Khan; Kiran Kumar Vattam; Parveen Jahan; Qurratulain Hasan; Pragna Rao
Journal:  Intractable Rare Dis Res       Date:  2016-02

Review 3.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

Review 4.  Genetic Dissection and Clinical Features of MODY6 (NEUROD1-MODY).

Authors:  Yukio Horikawa; Mayumi Enya
Journal:  Curr Diab Rep       Date:  2019-02-22       Impact factor: 4.810

5.  Examination of Rare Variants in HNF4 α in European Americans with Type 2 Diabetes.

Authors:  Jacklyn N Hellwege; Pamela J Hicks; Nicholette D Palmer; Maggie C Y Ng; Barry I Freedman; Donald W Bowden
Journal:  J Diabetes Metab       Date:  2011-10-20

6.  Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation.

Authors:  Nils Paulmann; Maik Grohmann; Jörg-Peter Voigt; Bettina Bert; Jakob Vowinckel; Michael Bader; Masa Skelin; Marko Jevsek; Heidrun Fink; Marjan Rupnik; Diego J Walther
Journal:  PLoS Biol       Date:  2009-10-27       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.